Key Takeaways:
- Dogwood Therapeutics has launched a pivotal Phase 2b trial for Halneuron.
- The average analyst price target suggests a potential downside of 30.88% from the current stock price.
- Brokerage recommendations place the stock in the "Outperform" category.
Phase 2b Trial Launch for Halneuron
Dogwood Therapeutics (NASDAQ: DWTX) has embarked on an ambitious Phase 2b trial for its promising candidate, Halneuron, specifically addressing chemotherapy-induced neuropathic pain. This critical study will evaluate the safety and efficacy of Halneuron over a four-week period, with an interim analysis planned before the year's end. With an adaptable trial design aimed at enhancing outcomes, Dogwood anticipates enrolling approximately 200 patients.
Wall Street Analysts Forecast
According to the latest projections from three analysts, the one-year price target for Dogwood Therapeutics Inc. (DWTX, Financial) averages at $3.00. The price targets span a high of $5.00 and a low of $1.00, suggesting a potential downside risk of 30.88% from the current trading price of $4.34. For additional insights, please visit the Dogwood Therapeutics Inc. (DWTX) Forecast page on GuruFocus.
Brokerage Recommendations
Dogwood Therapeutics finds favor among analysts, with an average brokerage recommendation score of 2.5, categorizing it as "Outperform." This consensus emanates from two brokerage firms and is based on a rating scale of 1 to 5, where 1 represents a Strong Buy and 5 signifies a Sell. This optimistic stance reflects a broader confidence in the company's strategic trajectory and potential market performance.
